Linked Life Data

11991839

Source:http://linkedlifedata.com/resource/pubmed/id/11991839

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2002-5-6
pubmed:abstractText
There is compelling evidence that MHC-driven immune processes play a dominant role in the development of cardiac allograft vasculopathy. Thus, it makes intuitive sense that tolerance, which eliminates donor alloreactivity, should protect against CAV. However, in the experimental literature, there are examples of CAV occurring in recipients rendered tolerant by either peripheral or central induction protocols. Why does transplant arteriopathy occur in recipients that have achieved a robust state of tolerance or in the animals devoid of T or B cell immunity? There may be immunological blindspots that persist even after a state of tolerance is achieved. These blindspots could contribute to the pathogenesis of chronic rejection (CR).
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1093-4715
pubmed:author
pubmed:issnType
Electronic
pubmed:day
1
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
e116-8
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Overcoming cardiac allograft vasculopathy (CAV) by inducing tolerance.
pubmed:affiliation
The Transplantation Biology Research Center, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Review, Research Support, Non-U.S. Gov't